Having trouble accessing articles? Reset your cache.

Teriflunomide: Additional Phase III data

Additional data from the double-blind, international Phase III TEMSO trial in 1,088 patients showed that once-daily 7 and 14 mg oral teriflunomide significantly reduced ARR from baseline to 2

Read the full 291 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE